Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.
Farnesyltransferase inhibitors (FTIs) represent a new class of signal transduction inhibitors that block the processing of cellular polypeptides that have cysteine terminal residues and, by so doing, interdict multiple pathways involved in proliferation and survival of diverse malignant cell types. Tipifarnib is an orally bioavailable, nonpeptidomimetic methylquinolone FTI that has exhibited clinical activity in patients with myeloid malignancies including elderly adults with acute myelogenous leukemia (AML) who are not candidates for traditional cytotoxic chemotherapy, patients with high-risk myelodysplasia, myeloproliferative disorders, and imatinib-resistant chronic myelogenous leukemia. Because of its relatively low toxicity profile, tipifarnib provides an important alternative to traditional cytotoxic approaches for elderly patients who are not likely to tolerate or even benefit from aggressive chemotherapy. In this review, we will focus on the clinical development of tipifarnib for treatment of newly diagnosed AML, both as induction therapy for elderly adults with poor-risk AML and as maintenance therapy following achievement of first complete remission following induction and consolidation therapies for poor-risk AML. As with all other malignancies, the optimal approach is likely to lie in rational combinations of tipifarnib with cytotoxic, biologic and/or immunomodulatory agents with non-cross-resistant mechanisms of action. Gene expression profiling has identified networks of differentially expressed genes and gene combinations capable of predicting response to single agent tipifarnib. The clinical and correlative laboratory trials in progress and under development will provide the critical foundations for defining the optimal roles of tipifarnib and in patients with AMl and other hematologic malignancies.
Karp
Judith E
JE
Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA;
Lancet
Jeffrey E
JE
Leukemia. 2009 Apr;23(4):631-4
19092853
Leukemia. 2007 Sep;21(9):1964-70
17581608
Annu Rev Pharmacol Toxicol. 2001;41:53-77
11264450
Clin Cancer Res. 2007 Apr 1;13(7):2254-60
17404110
Blood. 2008 Mar 1;111(5):2589-96
18160667
Blood. 2001 Aug 1;98(3):548-53
11468148
Blood. 2009 Aug 6;114(6):1166-73
19470696
Oncogene. 1999 Dec 9;18(52):7514-26
10602510
Hematol Oncol Clin North Am. 2000 Feb;14(1):251-67
10680081
Trends Biochem Sci. 2003 Nov;28(11):573-6
14607085
Leuk Res. 2003 Apr;27(4):313-21
12531222
J Clin Oncol. 2007 May 10;25(14):1908-15
17488990
Leukemia. 1997 Aug;11(8):1193-6
9264368
Blood. 2007 Feb 15;109(4):1387-94
17082323
Blood. 2001 Sep 1;98(5):1302-11
11520775
Blood. 1999 Aug 1;94(3):1086-99
10419902
Curr Treat Options Oncol. 2006 Jul;7(4):285-94
16916489
Blood. 2006 Sep 1;108(5):1677-83
16670265
Science. 2006 Mar 31;311(5769):1887-93
16543417
Blood. 2007 Sep 15;110(6):2102-9
17536018
Clin Cancer Res. 2002 Jun;8(6):2002-9
12060646
Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40
12042765
J Clin Oncol. 1999 Dec;17(12):3835-49
10577857
J Clin Oncol. 2004 Apr 1;22(7):1287-92
15051776
Lancet. 1982 Dec 11;2(8311):1345-6
6128632
J Biol Chem. 1995 Apr 21;270(16):9031-4
7721814
Ann Hematol. 2006 Mar;85(3):139-63
16391911
J Clin Oncol. 2005 Mar 20;23(9):1969-78
15632409
Semin Oncol. 2004 Feb;31(1 Suppl 1):28-39
14981578
Blood. 2006 May 1;107(9):3481-5
16455952
Blood. 2001 Sep 1;98(5):1312-20
11520776
Invest New Drugs. 1999;17(3):241-58
10665477
Blood. 2007 Jun 15;109(12):5151-6
17351110
Blood. 1990 Jan 1;75(1):27-32
2403818
Science. 2006 Mar 17;311(5767):1621-3
16484451
J Biol Chem. 1999 Sep 17;274(38):27010-7
10480914
Haematologica. 2003 Feb;88(2):229-30
12604418
J Clin Oncol. 2006 Jun 1;24(16):2480-9
16735702
Proc Natl Acad Sci U S A. 1991 May 1;88(9):3812-6
2023931
Blood. 2001 Jun 1;97(11):3361-9
11369625
Blood. 2005 Aug 15;106(4):1355-61
15860663
Mol Pharmacol. 2005 Aug;68(2):477-86
15901852
Blood. 1992 Apr 15;79(8):1924-30
1562720
Am J Clin Pathol. 2003 May;119(5):672-80
12760285
Blood. 2006 Jul 15;108(2):685-96
16597596
Blood. 2007 May 15;109(10):4158-63
17264294
Clin Cancer Res. 2005 Aug 15;11(16):6057-64
16115951
Nature. 2006 Oct 12;443(7112):713-6
16964241
Blood. 2005 Nov 15;106(10):3532-7
16051737
Mol Cancer Ther. 2004 Feb;3(2):179-86
14985458
Ann Hematol. 2005 Apr;84(4):227-31
15517268
Leukemia. 2007 Apr;21(4):739-46
17268526
Blood. 2003 Dec 15;102(13):4527-34
12947010
Cancer Invest. 2007 Sep;25(6):484-94
17882662
Blood. 2004 Oct 1;104(7):1940-51
15217827
Leukemia. 1999 Jun;13(6):843-9
10360370
Mol Pharmacol. 2005 Jun;67(6):1991-8
15738311
Clin Cancer Res. 2006 Jan 15;12(2):591-9
16428505
Blood. 2007 Jan 15;109(2):431-48
16960150
BMC Cancer. 2004 Aug 25;4:56
15329151
J Clin Oncol. 1998 Mar;16(3):872-81
9508168
Cancer Res. 1996 Jun 1;56(11):2626-32
8653708
Blood. 2000 Sep 1;96(5):1655-69
10961860
J Lipid Res. 2006 Jan;47(1):15-31
16278491
Eur J Haematol. 2004 Dec;73(6):418-26
15522064
J Biol Chem. 2003 Aug 29;278(35):32493-6
12842888
Blood. 2003 Mar 1;101(5):1692-7
12411300
N Engl J Med. 2004 Apr 15;350(16):1605-16
15084693
Oncogene. 1994 Feb;9(2):621-8
8290273
Eur J Haematol. 2005 May;74(5):418-23
15813916
Mol Cell Biol. 2000 Jan;20(1):139-48
10594016
Nat Rev Cancer. 2003 Dec;3(12):945-51
14737124